Experience of Subgroup Analysis in Small Clinical Trials
View Presentation Matthew Guo, Amgen *Kun Nie, Amgen Inc. Keywords: subgroup analysis This presentation is motivated by the experience of a subgroup analysis of an orphan drug. Analyses within subgroups are common in clinical studies but subgroups based on post-randomization measures should be avoided. Particularly, subgroup analysis by response status after randomization could lead to improper inference if not conducted and interpreted cautiously. Benefits and limitations of such subgroup analysis will be discussed. Examples of such subgroup analysis in small clinical trials will be given. Statistical methods and outcomes will be presented.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC